FINWIRES · TerminalLIVE
FINWIRES

Sino Biopharmaceutical Plans HK$2 Billion Stock Buyback

By

Sino Biopharmaceutical (HKG:1177) has approved a plan to spend up to HK$2 billion over the next 12 months on share repurchases in the open market, according to a filing with the Hong Kong Exchange on Monday.

The approved amount may be used for shares repurchased directly by the biotech firm as well as shares acquired by the trustee administering its restricted share award scheme.

Since the start of 2026, the company has spent about HK$338 million to acquire 60.35 million shares under its repurchase program.

Related Articles

Asia

Asia Commercial Forecasts Rise in Full-Year Profit

Asia Commercial (HKG:0104) expects a net profit of at least HK$39 million for the year ended March 31, up from HK$24 million a year prior, according to a Friday Hong Kong bourse filing.The watch seller attributed the forecast to a reduction in fair value losses on investment properties.

$HKG:0104
Asia

Central Plains Environment Protection Subsidiary to Establish Clean Energy Supply Company

Central Plains Environment Protection (SHE:000544) wholly-owned subsidiary Zhengzhou Xinhong Reclaimed Water Resources Development and Utilization will invest 10 million yuan to establish a clean energy supply company.The newly-established company will utilize local reclaimed water, geothermal, and other resources, according to a Friday filing with the Shenzhen bourse.

$SHE:000544
Asia

OKG Technology Warns of Wider Fiscal-Year Loss

OKG Technology (HKG:1499) expects an attributable loss of at least HK$20 million for the year ended March 31, compared with HK$15.8 million a year prior, according to a Friday Hong Kong bourse filing.The construction engineering company attributed the forecast to a lower revenue from the foundation, building construction work, and ancillary services segment.

$HKG:1499